GSK wins jury verdict in Illinois ranitidine cancer case

GSK

GSK plc has welcomed today’s jury verdict in the Joiner case in Illinois state court finding in GSK’s favour.

·   Jury in Joiner case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer

·   Verdict is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer

·   GSK will continue to vigorously defend itself against all other claims

This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epidemiological studies looking at human data regarding the use of ranitidine. GSK will continue to vigorously defend itself against all other claims.

Prior to this verdict, the court rejected the Plaintiff’s ability to request punitive damages.

Share on:
Find more news, interviews, share price & company profile here for:
    GSK announces the EMA's review of Nucala (mepolizumab) as a potential add-on treatment for COPD, promising hope for 40 million patients battling this condition.
    GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor.
    GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates.
    GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns.
    GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results.
    GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe.

      Search

      Search